Interim Analysis of Phase 2 Results for Cemiplimab in Patients With Metastatic Basal Cell Carcinoma (mBCC) Who Progressed on or Are Intolerant to Hedgehog Inhibitors (HHIs). J of Skin 2021, 5 (1), s3. https://doi.org/10.25251/skin.5.supp.3.